Do Recent Randomized Trial Results Influence which Patients with Myelodysplastic Syndromes Receive Iron Chelation?

Gattermann, N

Gattermann, N (corresponding author), Heinrich Heine Univ Dusseldorf, Dept Hematol Oncol & Clin Immunol, Moorenstr 5, D-40225 Dusseldorf, Germany.

HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 2020; 34 (2): 465

Abstract

Iron overload (IOL) in patients with myelodysplastic syndromes (MDS) is mainly attributable to chronic transfusion therapy. The importance of iron che......

Full Text Link